Stock Analysis on Net
Stock Analysis on Net

Pfizer Inc. (NYSE:PFE)

Common-Size Income Statement
Quarterly Data

Pfizer Inc., common-size consolidated income statement (quarterly data)

Microsoft Excel
3 months ended: Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 31, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019
Product revenues 87.10 81.84 83.63 84.69 85.88 82.78 87.75 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Alliance revenues 10.73 15.56 14.60 13.11 12.19 15.12 11.14 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Royalty revenues 2.17 2.60 1.77 2.20 1.93 2.10 1.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Revenues (legacy) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Revenues 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Cost of sales -29.73 -24.84 -22.71 -51.90 -68.70 -24.89 -26.43 -39.73 -26.78 -31.17 -38.91 -40.84 -41.32 -37.02 -28.64 -24.98 -19.53 -18.51 -19.24 -20.55 -20.52 -19.42 -18.55
Gross profit 70.27% 75.16% 77.29% 48.10% 31.30% 75.11% 73.57% 60.27% 73.22% 68.83% 61.09% 59.16% 58.68% 62.98% 71.36% 75.02% 80.47% 81.49% 80.76% 79.45% 79.48% 80.58% 81.45%
Selling, informational and administrative expenses -18.33 -27.98 -23.49 -31.40 -24.32 -26.89 -18.49 -19.12 -14.98 -10.99 -10.10 -17.22 -12.06 -15.47 -19.13 -32.16 -25.86 -26.96 -25.20 -33.42 -25.71 -26.47 -25.45
Research and development expenses -14.68 -20.30 -16.76 -19.32 -20.09 -20.36 -13.55 -14.89 -11.91 -10.15 -8.97 -14.46 -11.15 -11.85 -13.74 -28.71 -22.38 -21.07 -16.58 -22.24 -18.00 -13.89 -12.98
Acquired in-process research and development expenses -0.07 -0.05 0.00 -0.50 -0.50 -0.25 -0.11 -0.30 -2.31 0.00 -1.38 -10.36 -3.17 -1.16 -0.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Amortization of intangible assets -7.41 -9.84 -8.79 -8.70 -8.74 -9.10 -5.97 -4.65 -3.63 -2.96 -3.25 -4.01 -4.03 -4.85 -5.91 -7.33 -8.39 -8.81 -8.42 -8.13 -9.56 -8.93 -9.02
Restructuring charges and certain acquisition-related costs -1.77 -9.44 -0.69 -17.61 -1.15 -1.65 -0.05 -3.27 -0.88 -0.68 -0.75 -0.57 -2.69 0.01 -0.15 -1.57 -0.02 -3.65 -0.54 -3.55 -2.88 0.87 -0.35
Operating income (loss) 28.01% 7.55% 27.57% -29.43% -23.50% 16.87% 35.40% 18.04% 39.50% 44.05% 36.64% 12.55% 25.58% 29.66% 32.30% 5.25% 23.82% 21.01% 30.02% 12.11% 23.33% 32.16% 33.65%
Gain on completion of Consumer Healthcare JV transaction 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.06 -0.01 63.78 0.00 0.00
Other income (deductions), net -1.38 -8.33 -4.58 1.09 -1.35 0.58 -1.48 3.50 0.26 -2.78 -1.36 3.51 7.06 7.10 6.92 3.82 -18.27 9.67 -1.89 -23.98 -2.51 -0.94 -0.70
Income (loss) from continuing operations before (provision) benefit for taxes on income (loss) 26.64% -0.78% 22.99% -28.34% -24.84% 17.44% 33.92% 21.53% 39.76% 41.26% 35.27% 16.05% 32.63% 36.76% 39.22% 9.06% 5.55% 30.68% 28.19% -11.89% 84.60% 31.22% 32.95%
(Provision) benefit for taxes on income (loss) -1.32 1.01 -1.97 5.45 7.14 0.55 -3.87 -0.95 -1.57 -5.66 -4.57 -1.04 1.36 -5.94 -5.57 -0.36 3.38 -4.28 -3.56 9.31 -24.03 6.90 -3.30
Income (loss) from continuing operations 25.31% 0.23% 21.02% -22.89% -17.70% 17.99% 30.05% 20.59% 38.19% 35.60% 30.70% 15.01% 34.00% 30.82% 33.65% 8.70% 8.92% 26.40% 24.63% -2.58% 60.57% 38.12% 29.65%
Discontinued operations, net of tax -0.05 0.13 -0.03 -0.17 0.09 -0.02 0.01 0.01 -0.10 0.12 -0.04 -0.78 -0.05 -1.25 0.01 2.54 5.45 9.05 8.74 0.00 0.03 0.00 0.00
Net income (loss) before allocation to noncontrolling interests 25.27% 0.36% 20.99% -23.06% -17.61% 17.97% 30.06% 20.60% 38.09% 35.73% 30.67% 14.23% 33.95% 29.57% 33.66% 11.25% 14.37% 35.45% 33.36% -2.58% 60.60% 38.12% 29.65%
Net income attributable to noncontrolling interests -0.05 -0.05 -0.05 -0.06 -0.04 -0.08 -0.07 -0.04 -0.07 -0.02 -0.02 0.01 -0.05 -0.14 -0.06 -0.09 -0.08 -0.08 -0.09 -0.08 -0.03 -0.08 -0.04
Net income (loss) attributable to Pfizer Inc. 25.22% 0.31% 20.94% -23.12% -17.65% 17.89% 29.98% 20.56% 38.02% 35.71% 30.65% 14.23% 33.89% 29.44% 33.60% 11.15% 14.29% 35.37% 33.27% -2.66% 60.57% 38.04% 29.61%
Preferred stock dividends, net of tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 -0.01 -0.01
Net income (loss) attributable to Pfizer Inc. common shareholders 25.22% 0.31% 20.94% -23.12% -17.65% 17.89% 29.98% 20.56% 38.02% 35.71% 30.65% 14.23% 33.89% 29.44% 33.60% 11.15% 14.29% 35.37% 33.27% -2.65% 60.57% 38.04% 29.60%

Based on: 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Income statement item Description The company
Operating income (loss) The net result for the period of deducting operating expenses from operating revenues. Pfizer Inc. operating income (loss) as a percentage of revenues decreased from Q1 2024 to Q2 2024 but then increased from Q2 2024 to Q3 2024 exceeding Q1 2024 level.
Income (loss) from continuing operations before (provision) benefit for taxes on income (loss) Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Pfizer Inc. income (loss) from continuing operations before (provision) benefit for taxes on income (loss) as a percentage of revenues decreased from Q1 2024 to Q2 2024 but then increased from Q2 2024 to Q3 2024 exceeding Q1 2024 level.
Net income (loss) attributable to Pfizer Inc. The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Pfizer Inc. net income (loss) attributable to Pfizer Inc. as a percentage of revenues decreased from Q1 2024 to Q2 2024 but then increased from Q2 2024 to Q3 2024 exceeding Q1 2024 level.